 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2014, vol. 20, issue 2
Subject Collection: Medicine
Pages: 506-509
DOI: 10.5272/jimab.2014202.506
Published online: 27 June 2014
J of IMAB 2014 Jan-Jun;20(2):506-509
SERUM YKL-40 LEVELS IN CHRONIC HEART FAILURE.
Maria Kazakova1, Petar Nikolov2, Kiril Simitchiev3, Fedya Nikolov2, Victoria Sarafian1
.
1) Department of Medical Biology, Medical Faculty, Medical University - Plovdiv,
2) Department of Cardiology, Medical Faculty, Medical University - Plovdiv,
3) Department of Analytical Chemistry and Computer Chemistry, Faculty of Chemistry, University of Plovdiv, Bulgaria.
ABSTRACT:
Inflammatory processes are involved in the pathogenesis and development of chronic heart disease. The promising novel inflammatory biomarker YKL-40 is related to the degree of inflammation and pathological tissue remodeling.
The aim of this study was to determine serum YKL-40 levels in patients with chronic heart failure and to evaluate the potential relationship with ultrasonography findings.
Forty-three individuals were enrolled in the study – 24 patients (10 females and 14 males) with chronic heart failure, aged 70±11 (mean ± standard deviation) and 16 healthy people as age-matched controls (above 50 years). The serum YKL-40 levels were assessed by ELISA. Sonographic measurements such as two-dimensional, Power wave, Continuous Wave, Colour mode and M-Mode were performed using a diagnostic ultrasound system (PHILIPS Ultrasound, Washington, US) with a L11-3 probe of 3-11 MHz. The six minute walk test was used to assess functional capability of patients.
Our study revealed significantly higher serum YKL-40 levels in patients compared to the control group (P=0.010). No relation was found between the glycoprotein and the results from the ultrasonographic and functional examination.
We suppose that increased serum YKL-40 levels in patients with chronic heart failure might reflect the inflammatory route in the development of the disease.
Key words: YKL-40, chronic heart failure, biomarker,
- Download FULL TEXT /PDF 547 KB/
Please cite this article as:
Kazakova M, Nikolov P, Simitchiev K, Nikolov F, Sarafian V. SERUM YKL-40 LEVELS IN CHRONIC HEART FAILURE. J of IMAB. 2014 Jan-Jun;20(2):506-509. doi: 10.5272/jimab.2014202.506.
Correspondence to: Dr. Victoria Sarafian, Department of Biology, Medical University – Plovdiv; 15a, Vasil Aprilov Blvd., 4000 Plovdiv, Bulgaria; E-mail: sarafian@abv.bg
REFERENCES:
1. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003 May 15;348(20):2007-2018. [PubMed] [CrossRef]
2. Damas JK, Gullestad L, Ueland T, Solum N, Simonsena S, Frølandd S, et al. CXC-chemokines, a new group of cytokines in congestive heart failuredpossible role of platelets and monocytes. Cardiovasc Res. 2000 Jan 14;45(2):428-436. [PubMed] [CrossRef]
3. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006 May;53(2):172-209. [PubMed]
4. Kzhyshkowska J, Krusell L. Cross-talk between endocytic clearance and secretion in macrophages. Immunobiology.2009 Jul;214(7):576–593. [PubMed] [CrossRef]
5. Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel). 2010 Jul 12;2(3):1453-1491. [PubMed] [CrossRef]
6. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoproein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumor necrosis factor-alpha. Biochem J. 2004 Jun 15;380(Pt 3):651–659. [PubMed] [CrossRef]
7. Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009 Nov 23;8:61. [PubMed] [CrossRef]
8. Xie F, Qian Q, Chen Z, Ma G, Feng Y. Chitinase 3-like 1 gene-329G/A polymorphism, plasma concentration and risk of coronary heart disease in a Chinese population. Gene. 2012 May 10;499(1):135-138. [PubMed] [CrossRef]
9. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008 Jan;155(1):75-81. [PubMed] [CrossRef]
10. Zheng JL, Lu L, Hu J, Zhang RY, Zhang Q, Chen QJ, et al. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis.2010 Jun;210(2):590–595. [PubMed] [CrossRef]
11. Mathiasen AB, Harutyunyan MJ, Jørgensen E, Helqvist S, Ripa R, Gøtze JP, et al. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand J Clin Lab Invest. 2011 Sep;71(5):439-447. [PubMed] [CrossRef]
12. Boot RG, van Achterberg TE, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis. Chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. 1999 Mar;19(3): 687–694. [PubMed] [CrossRef]
13. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003 Jul 1;287(1):79-87. [PubMed] [CrossRef]
14. Kucur M, Isman F, Karadag B, Vural V, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis. 2007 Aug;18(5):391–396. [PubMed] [CrossRef]
15. Oh JK. Echocardiography in heart failure: Beyond diagnosis. Eur J Echocardiogr. 2007 Jan;8(1):4-14. [PubMed] [CrossRef]
Received: 16 April 2014
Published online: 27 June 2014